Your browser is no longer supported. Please, upgrade your browser.
CLBS Caladrius Biosciences, Inc. daily Stock Chart
Caladrius Biosciences, Inc.
Index- P/E- EPS (ttm)-1.81 Insider Own3.50% Shs Outstand10.62M Perf Week16.00%
Market Cap31.10M Forward P/E- EPS next Y-0.93 Insider Trans0.00% Shs Float10.19M Perf Month5.73%
Income-19.00M PEG- EPS next Q-0.39 Inst Own17.20% Short Float1.67% Perf Quarter-11.55%
Sales- P/S- EPS this Y-12.40% Inst Trans40.83% Short Ratio0.35 Perf Half Y-31.42%
Book/sh1.62 P/B1.25 EPS next Y40.40% ROA-64.70% Target Price- Perf Year-21.92%
Cash/sh1.35 P/C1.50 EPS next 5Y- ROE-81.50% 52W Range1.05 - 3.64 Perf YTD-19.12%
Dividend- P/FCF- EPS past 5Y35.50% ROI- 52W High-44.23% Beta1.49
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin- 52W Low93.33% ATR0.15
Employees27 Current Ratio4.60 Sales Q/Q- Oper. Margin- RSI (14)55.35 Volatility10.02% 7.97%
OptionableYes Debt/Eq0.00 EPS Q/Q13.80% Profit Margin- Rel Volume0.69 Prev Close2.00
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout- Avg Volume491.06K Price2.03
Recom2.20 SMA2010.42% SMA506.88% SMA200-12.09% Volume339,024 Change1.50%
May-18-20Downgrade Dawson James Buy → Neutral
Nov-20-18Resumed H.C. Wainwright Buy $18.50
Aug-23-16Initiated Chardan Capital Markets Buy $6.50
Apr-29-16Upgrade H.C. Wainwright Neutral → Buy $1.25
Jan-08-16Downgrade H.C. Wainwright Buy → Neutral
Jan-07-16Downgrade Maxim Group Buy → Hold
Dec-22-15Reiterated Maxim Group Buy $12 → $4
Jun-02-20 08:06AM  
May-28-20 01:20PM  
May-26-20 08:00AM  
May-14-20 03:42PM  
May-13-20 12:16AM  
May-12-20 11:15AM  
May-07-20 04:05PM  
May-06-20 08:30AM  
Apr-30-20 08:30AM  
Apr-27-20 03:16PM  
Apr-23-20 02:00PM  
Apr-22-20 08:00AM  
Apr-20-20 07:14AM  
Mar-26-20 10:17AM  
Mar-17-20 07:00AM  
Mar-06-20 09:22AM  
Mar-05-20 04:05PM  
Feb-27-20 08:30AM  
Feb-03-20 08:30AM  
Jan-27-20 09:17AM  
Jan-21-20 07:35AM  
Jan-07-20 04:05PM  
Dec-02-19 04:05PM  
Nov-25-19 08:56AM  
Nov-19-19 05:56PM  
Nov-16-19 03:59PM  
Nov-06-19 04:05PM  
Nov-04-19 08:44AM  
Oct-31-19 08:30AM  
Oct-30-19 08:30AM  
Oct-23-19 11:30AM  
Oct-14-19 11:58AM  
Oct-01-19 08:30AM  
Sep-24-19 09:04AM  
Sep-06-19 10:15AM  
Sep-05-19 04:05PM  
Sep-04-19 08:58AM  
Aug-15-19 09:57AM  
Aug-08-19 04:05PM  
Aug-07-19 08:30AM  
Aug-05-19 10:55AM  
Aug-01-19 08:30AM  
Jul-25-19 03:04PM  
Jul-15-19 08:30AM  
Jun-04-19 08:30AM  
May-24-19 03:53AM  
May-09-19 04:05PM  
May-07-19 08:30AM  
May-02-19 08:30AM  
Apr-25-19 02:23PM  
Apr-03-19 08:30AM  
Mar-14-19 04:23PM  
Mar-13-19 04:05PM  
Mar-11-19 02:20PM  
Feb-13-19 05:26PM  
Feb-05-19 08:00AM  
Jan-23-19 09:04AM  
Jan-07-19 08:00AM  
Nov-15-18 07:25AM  
Nov-09-18 08:30AM  
Nov-08-18 04:05PM  
Nov-02-18 08:00AM  
Oct-01-18 08:36AM  
Sep-27-18 08:00AM  
Sep-21-18 11:24AM  
Sep-12-18 09:30AM  
Sep-11-18 08:00AM  
Aug-09-18 04:05PM  
Aug-02-18 08:00AM  
Jun-20-18 08:00AM  
Jun-19-18 08:00AM  
Jun-05-18 08:00AM  
May-10-18 04:05PM  
May-07-18 08:00AM  
May-03-18 08:00AM  
Apr-20-18 07:20AM  
Apr-10-18 08:00AM  
Apr-09-18 04:00PM  
Apr-03-18 08:00AM  
Mar-22-18 04:05PM  
Mar-15-18 08:00AM  
Mar-13-18 08:00AM  
Mar-08-18 04:05PM  
Mar-06-18 08:00AM  
Feb-07-18 08:00AM  
Jan-18-18 08:00AM  
Dec-08-17 12:33PM  
Dec-01-17 08:30AM  
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. Its product candidates include developmental treatments for cardiovascular diseases, such as CLBS12 for the treatment of critical limb ischemia; CLBS16, which is in Phase II clinical trial for the treatment of coronary microvascular dysfunction; CLBS14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in Basking Ridge, New Jersey.